Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor

NCT ID: NCT01985256

Last Updated: 2018-05-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 17 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-02-28
• Study Completion Date: 2016-03-03

Brief Summary

This is a multicenter study evaluating the safety and tolerability of Toca 511 administered intravenously to patients with recurrent or progressive Grade III or Grade IV Gliomas who have elected to undergo surgical removal of their tumor. Patients meeting all of the inclusion and none of the exclusion criteria will receive an initial dose of Toca 511 administered as an intravenous, bolus injection, followed approximately 11 days later by an additional dose injected into the walls of the resection cavity at the time of planned tumor resection. Approximately 6 weeks later, patients will begin treatment with oral Toca FC, an antifungal agent, and repeated every 4 weeks. All patients enrolled in this study will be encouraged to participate in a continuation protocol that enables additional Toca FC administration and the collection of long-term safety and response data.

Conditions

Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single Arm

Toca 511 vector/Toca FC

Group Type: EXPERIMENTAL

Toca 511

Intervention Type: BIOLOGICAL

All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene, intravenously and then intracranially. CD converts the antifungal 5-fluorocytosine (5-FC) to the anti-cancer drug 5-fluorouracil (5-FU) in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after the second administration of Toca 511,patients will begin 7-day course of oral 5-FC, repeated every 4 weeks for the duration of the study.

Toca FC

Intervention Type: DRUG

Interventions

Toca 511

All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene, intravenously and then intracranially. CD converts the antifungal 5-fluorocytosine (5-FC) to the anti-cancer drug 5-fluorouracil (5-FU) in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after the second administration of Toca 511,patients will begin 7-day course of oral 5-FC, repeated every 4 weeks for the duration of the study.

Intervention Type: BIOLOGICAL

Toca FC

Intervention Type: DRUG

Other Intervention Names

vocimagene amiretrorepvec; retroviral replicating vector (RRV); flucytosine, 5-FC, 5-FC XR, Toca FC

Eligibility Criteria

Inclusion Criteria

• Has the subject given written informed consent?
• Is the subject between 18 years old and 80 years old inclusive?
• Has the subject had histologically proven HGG with recurrence or progression following initial definitive therapy(s) such as surgery with or without adjuvant radiation therapy and/or chemotherapy (confirmed by diagnostic biopsy or contrast-enhanced MRI and evaluable by Macdonald criteria)? Note, if first recurrence of HGG is documented by MRI, an interval of at least 12 weeks after the end of prior radiation therapy is required unless there is either: i) histopathologic confirmation of recurrent tumor, or ii) new enhancement on MRI outside of the radiotherapy treatment field.
• Does the patient have either (1) a single, enhancing tumor recurrence/progression that is ≤ 8 cm in greatest dimension, or (2) multiple enhancing tumor recurrences/progressions within the same surgical field where the sum of their greatest dimensions is ≤ 8 cm?
• Based on the pre-operative evaluation, is the tumor recurrence/progression a candidate for ≥ 80% resection?
• Has the subject elected not to undergo treatment with the Gliadel® wafer?
• Does the subject have a Karnofsky performance status ≥ 70?
• Does the subject have an absolute neutrophil count (ANC) ≥ 1500/mm3?
• Does the subject have an absolute lymphocyte count ≥ 500/mm3?
• Does the subject have a platelet count ≥ 100,000/mm3?
• Does the subject have a Hgb ≥ 10 g/dL?
• Does the subject have a coagulation profile that would allow for the safe performance of surgery under general anesthesia?
• Does the subject have an estimated glomerular filtration rate of at least 50 mL/min (inclusive) by the Cockcroft-Gault formula?
• Does the subject have an ALT < 3 times the upper limit of the laboratory reference range and total bilirubin < 1.5 mg/dL?
• If the subject is a female of childbearing potential, has she had a negative serum pregnancy test within the past 21 days?
• Is the subject willing to use condoms for contraception for 6 months after receiving Toca 511 or until there is no evidence of the virus in his/her blood, whichever is longer. If the subject is a fertile female, is she willing to use contraception for at least 12 months?
• Is the subject willing and able to abide by the protocol?
• Does the subject have adequate venous access?

Exclusion Criteria

• Has the subject received cytotoxic chemotherapy within the past 3 weeks (6 weeks for nitrosoureas) of the planned date of vector injection?
• Does the subject have, or has the subject had, within the past 4 weeks any infection requiring antibiotic, antifungal or antiviral therapy?
• Has the subject received Avastin® (bevacizumab) for this recurrence/progression, or within the 4 weeks prior to planned Visit 1?
• Does the subject have any bleeding diathesis, or must the subject take any anticoagulants, or antiplatelet agents, including NSAIDs that cannot be stopped for surgery?
• Does the subject have a history of allergy or intolerance to flucytosine?
• Is the subject HIV positive?
• Does the subject have any gastrointestinal disease that would prevent him or her from being able to swallow or absorb flucytosine?
• Has the subject received any investigational treatment within the past 30 days?
• Is the subject breastfeeding?
• Does the patient have a history of prior malignancy, excluding basal or squamous cell carcinoma of the skin, with an expected survival of less than five years?

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tocagen Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Asha Das, MD

Role: STUDY_DIRECTOR

Tocagen Inc.

Steven Kalkanis, MD

Role: PRINCIPAL_INVESTIGATOR

Henry Ford Hospital

Locations

UC Irivine

Irvine, California, United States

UCLA

Los Angeles, California, United States

UC San Diego, Moores Cancer Center

San Diego, California, United States

Henry Ford Hospital

Detroit, Michigan, United States

JFK Medical Center New Jersery

Edison, New Jersey, United States

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Countries

United States

References

Ostertag D, Amundson KK, Lopez Espinoza F, Martin B, Buckley T, Galvao da Silva AP, Lin AH, Valenta DT, Perez OD, Ibanez CE, Chen CI, Pettersson PL, Burnett R, Daublebsky V, Hlavaty J, Gunzburg W, Kasahara N, Gruber HE, Jolly DJ, Robbins JM. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro Oncol. 2012 Feb;14(2):145-59. doi: 10.1093/neuonc/nor199. Epub 2011 Nov 9.

Reference Type: BACKGROUND

PMID: 22070930 (View on PubMed)

Other Identifiers

Tg 511-13-01

Identifier Type: -

Identifier Source: org_study_id